ECSP034489A - Farmacos para ligandos del receptor nmda - Google Patents

Farmacos para ligandos del receptor nmda

Info

Publication number
ECSP034489A
ECSP034489A EC2003004489A ECSP034489A ECSP034489A EC SP034489 A ECSP034489 A EC SP034489A EC 2003004489 A EC2003004489 A EC 2003004489A EC SP034489 A ECSP034489 A EC SP034489A EC SP034489 A ECSP034489 A EC SP034489A
Authority
EC
Ecuador
Prior art keywords
pharmacos
nmda
ligands
nmda receiver
receiver ligands
Prior art date
Application number
EC2003004489A
Other languages
English (en)
Inventor
Bernd Buettelmann
Georg Jaeschke
Emmanuel Pinard
Alexander Alanine
Rene Wyler
Joerg Huwyler
Holger Fisher
Marie Paule Neidhart
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP034489A publication Critical patent/ECSP034489A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a compuestos de fórmula general los cuales son de utilidad para el tratamiento de enfermedades relacionadas con el receptor del NMDA.Estos compuestos pueden ser empleados como profármacos para el compuesto madre de fórmula, los cuáles son de utilidad para el tratamiento de enfermedades relacionadas con el receptor del NMDA.
EC2003004489A 2000-08-21 2003-02-20 Farmacos para ligandos del receptor nmda ECSP034489A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00117918 2000-08-21

Publications (1)

Publication Number Publication Date
ECSP034489A true ECSP034489A (es) 2003-03-31

Family

ID=8169594

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004489A ECSP034489A (es) 2000-08-21 2003-02-20 Farmacos para ligandos del receptor nmda

Country Status (35)

Country Link
US (1) US6407235B1 (es)
EP (1) EP1313703B1 (es)
JP (1) JP4162991B2 (es)
KR (1) KR100589991B1 (es)
CN (1) CN1227230C (es)
AR (1) AR030373A1 (es)
AT (1) ATE386022T1 (es)
AU (2) AU8589401A (es)
BR (1) BR0113348A (es)
CA (1) CA2419279C (es)
CY (1) CY1107937T1 (es)
CZ (1) CZ303319B6 (es)
DE (1) DE60132782T2 (es)
DK (1) DK1313703T3 (es)
EC (1) ECSP034489A (es)
EG (1) EG24293A (es)
ES (1) ES2299508T3 (es)
HR (1) HRP20030125B1 (es)
HU (1) HU229802B1 (es)
IL (1) IL154254A0 (es)
JO (1) JO2289B1 (es)
MA (1) MA26947A1 (es)
MX (1) MXPA03001311A (es)
MY (1) MY136065A (es)
NO (1) NO324941B1 (es)
NZ (1) NZ523990A (es)
PA (1) PA8525601A1 (es)
PE (1) PE20020291A1 (es)
PL (1) PL204215B1 (es)
PT (1) PT1313703E (es)
RS (1) RS51467B (es)
RU (1) RU2272027C2 (es)
SI (1) SI1313703T1 (es)
WO (1) WO2002016321A1 (es)
ZA (1) ZA200300894B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520657A (en) * 2000-03-21 2004-11-26 Procter & Gamble Heterocyclic side chain containing, N-substituted metalloprotease inhibitors
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
JP2009521424A (ja) * 2005-12-19 2009-06-04 メチルジーン インコーポレイテッド 抗真菌剤の活性を増強するためのヒストンデアセチラーゼ阻害剤
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
MX2009006542A (es) 2006-12-19 2009-06-30 Methylgene Inc Inhibidores de histona desacetilasa y sus profarmacos.
RS58991B1 (sr) 2013-11-05 2019-08-30 Astrazeneca Ab Prolekovi nmda antagonista

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020587A1 (en) * 1994-01-31 1995-08-03 Pfizer Inc. Neuroprotective chroman compounds
DE4410822A1 (de) 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
TWI254043B (en) 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor

Also Published As

Publication number Publication date
CY1107937T1 (el) 2013-09-04
BR0113348A (pt) 2003-07-08
EP1313703B1 (en) 2008-02-13
RS51467B (sr) 2011-04-30
DE60132782D1 (de) 2008-03-27
PL204215B1 (pl) 2009-12-31
JP4162991B2 (ja) 2008-10-08
DE60132782T2 (de) 2009-02-05
HRP20030125A2 (en) 2005-02-28
NO324941B1 (no) 2008-01-07
PT1313703E (pt) 2008-03-25
PA8525601A1 (es) 2002-04-25
NO20030781D0 (no) 2003-02-19
ATE386022T1 (de) 2008-03-15
AU2001285894B2 (en) 2006-06-15
EP1313703A1 (en) 2003-05-28
HUP0301548A3 (en) 2010-03-29
CA2419279C (en) 2008-10-14
ZA200300894B (en) 2004-04-30
RU2272027C2 (ru) 2006-03-20
HRP20030125B1 (en) 2011-07-31
CA2419279A1 (en) 2002-02-28
US6407235B1 (en) 2002-06-18
WO2002016321A1 (en) 2002-02-28
IL154254A0 (en) 2003-09-17
MY136065A (en) 2008-08-29
US20020040037A1 (en) 2002-04-04
CN1227230C (zh) 2005-11-16
SI1313703T1 (sl) 2008-06-30
JP2004506715A (ja) 2004-03-04
JO2289B1 (en) 2005-09-12
ES2299508T3 (es) 2008-06-01
CZ303319B6 (cs) 2012-08-01
YU13003A (sh) 2006-05-25
HU229802B1 (hu) 2014-07-28
KR100589991B1 (ko) 2006-06-15
NZ523990A (en) 2004-09-24
HK1059083A1 (en) 2004-06-18
CZ2003492A3 (cs) 2004-01-14
AU8589401A (en) 2002-03-04
HUP0301548A2 (hu) 2003-08-28
PL361387A1 (en) 2004-10-04
EG24293A (en) 2009-01-08
DK1313703T3 (da) 2008-05-19
NO20030781L (no) 2003-02-19
MXPA03001311A (es) 2003-06-30
AR030373A1 (es) 2003-08-20
PE20020291A1 (es) 2002-04-17
KR20030022417A (ko) 2003-03-15
CN1447793A (zh) 2003-10-08
MA26947A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
UY27551A1 (es) Derivados de benzotiazol
CY1109088T1 (el) Μεθοδος για την παρασκευη υποκατεστημενων ενωσεων 3-αρυλο-βουτυλ-αμινης
UY28290A1 (es) Compuestos farmacéuticos novedosos
ECSP066447A (es) Derivados de isoquinolina 1,4-disustituida como inhibidores raf-quinasa útiles para el tratamiento de enfermedades proliferativas
PA8527001A1 (es) Poliarilcarboxamidas utiles como agentes reductores de lipidos
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
AR018705A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos.
ES2092113T3 (es) Derivados fluoroalcoxibencilamino de heterociclos que contienen nitrogeno.
CR20120294A (es) Compuestos tricíclicos novedosos
GT200500102A (es) Compuestos de aril-o-heteroarilamida ortosustituidos
ECSP034428A (es) Ciclopentanoindoles, composiciones conteniendo tales compuestos y su uso
CO6382083A2 (es) Compuestos triciclicos novedosos
MXPA03001186A (es) Compuestos heterociclicos como ligandos del receptor acido gamma aminobutirico (gabaa).
PA8524401A1 (es) DERIVADOS DE 4-Fenil-piridin
GT200500296A (es) Sintesis asimetrica de derivados del dehidrobenzofurano
UY27026A1 (es) Derivados benzodiacepínicos como moduladores de los receptores gaba a
SV2010003501A (es) Fungicidas novedosos
ES2159488B1 (es) Procedimiento para la preparacion de derivados de pirimidona con actividad antifungica.
NO20074047L (no) Ny fremgangsmate for fremstilling av substituerte indoler
EA200600605A1 (ru) Перегруппированные пентанолы, способ их получения и их применение в качестве противовоспалительных средств
ECSP045027A (es) Agonistas muscarinicos
PL376896A1 (pl) Sposoby wytwarzania 5-androstenów podstawionych w pozycji C-7
ECSP045396A (es) Proceso para preparar derivados de 6-alquiliden penem
ECSP034489A (es) Farmacos para ligandos del receptor nmda
UY27770A1 (es) Imidazolinilmetil aralquilsulfonamidas